These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


116 related items for PubMed ID: 2172266

  • 1. High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up.
    Huber R, Müller W, Banks MC, Rogers SJ, Norwood PC, Doyle E.
    J Chromatogr; 1990 Aug 03; 529(2):389-401. PubMed ID: 2172266
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
    Bliesath H, Huber R, Hartmann M, Lühmann R, Wurst W.
    Int J Clin Pharmacol Ther; 1994 Jan 03; 32(1):44-50. PubMed ID: 8199751
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Direct injection/h.p.l.c. methods for the analysis of drugs in biological samples.
    Doyle E, Huber R, Picot VS.
    Xenobiotica; 1992 Jul 03; 22(7):765-74. PubMed ID: 1333685
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
    Simon B, Müller P, Bliesath H, Lühmann R, Hartmann M, Huber R, Wurst W.
    Aliment Pharmacol Ther; 1990 Jun 03; 4(3):239-45. PubMed ID: 1966542
    [Abstract] [Full Text] [Related]

  • 10. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA, Büdingen C, Fahr S, Kinder B, Koske M.
    Biochem Pharmacol; 1991 Jul 05; 42(2):347-55. PubMed ID: 1650212
    [Abstract] [Full Text] [Related]

  • 11. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
    Kohl B, Sturm E, Senn-Bilfinger J, Simon WA, Krüger U, Schaefer H, Rainer G, Figala V, Klemm K.
    J Med Chem; 1992 Mar 20; 35(6):1049-57. PubMed ID: 1313110
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography.
    Koçyiğit-Kaymakçoğlu B, Unsalan S, Rollas S.
    Pharmazie; 2006 Jul 20; 61(7):586-9. PubMed ID: 16889064
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
    Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW.
    Pharmacology; 1998 Feb 20; 56(2):57-70. PubMed ID: 9494064
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.